TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31702058
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment in groups (MBT-G)
Study: 19663523
Drug: Armodafinil (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (50, 100, 200, 250, 300 or 400 mg)
Study: 17277001
Drug: Ibandronate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (oral or intravenous) at different doses and for variable time intervals
Study: 17277001
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of ibandronate
Study: 8021734
Drug: 5 daily
Normalized name: Alberto VO5 Daily Revitalizing Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 daily 2-hour infusions of 100 mg/m2
Study: 8021734
Drug: 8 daily
Normalized name: tobramycin 28 MG inhalation powder 8 Daily Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 daily 75-minute infusions of 62.5 mg/m2
Study: 2595106
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg over 20 min, followed by 0.9 mg/kg/h)
Study: 4402080
Drug: Indoramin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (20 mg.)
Study: 4402080
Drug: Indoramin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (40 mg.)
Study: 4402080
Drug: Indoramin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (10 mg.)
Study: 31647087
Drug: Daily red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily red wine vinegar ingestion for 8 weeks
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with low dose (30 mW, 10 J/cm2, 9 s per point, 810 nm)
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with high dose (100 mW, 40 J/cm2, 11 s per point, 810 nm)
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with low dose + Gluma Desensitizer
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with high dose + Gluma Desensitizer
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with low dose + Nd:YAG laser
Study: 28391435
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser with high dose + Nd:YAG laser
Study: 26333366
Drug: Peripheral G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral G‐CSF combined with IC BMC therapy
Study: 26333366
Drug: Peripheral G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral G‐CSF
Study: 26333366
Drug: Peripheral G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral G‐CSF and IC serum
Study: 21876298
Drug: FES-therapy combined
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES-therapy combined with progressive limb loading
Study: 19478489
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (PT) during pregnancy
Study: 12182772
Drug: Surgery, interstitial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine (BCNU)
Study: 9440482
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.1 IU/kg daily
Study: 9440482
Drug: Prednisolone 25
Normalized name: prednisolone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 25 mg morning and evening
Study: 9440482
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) plus Prednisolone
Study: 7975785
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. (n = 25)
Study: 7975785
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d. (n = 25)
Study: 28433211
Drug: Ketamine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine monotherapy (KM) 1 mg/kg i.v. (with up to three additional doses of 0.5 mg/kg each)
Study: 28433211
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of ketamine and propofol (CoKP) 0.5 mg/kg each i.v. (with up to three additional doses of 0.25 mg/kg each)
Study: 28433211
Drug: Ketamine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine monotherapy (KM)
Study: 28433211
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of ketamine and propofol (CoKP)
Study: 26054140
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion at 'Xiasanhuang', once a day, with an interval of 2 days after every 10 treatments for 2 months.
Study: 26054140
Drug: Benazepril hydrochloride,
Normalized name: Benazepril Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril hydrochloride, 5 to 10 mg orally, once a day for 2 months.
Study: 17409109
Drug: Carvedilol at
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol at a dose of 10-20 mg/day (mean dose: 16 +/- 4 mg/day) for a mean of 12 +/- 1 months
Study: 15747470
Drug: Cefotiam hexetil
Normalized name: Cefotiam hexetil hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam hexetil 200 mg bid over a 5 day period followed by 5 days of placebo
Study: 15747470
Drug: Cefotiam hexetil
Normalized name: Cefotiam hexetil hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam hexetil 200 mg bid over a 10 day period
Study: 8322791
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose OKT3 (5 mg)
Study: 7993573
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3 (2 mg)
Study: 3521443
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus amiloride (25 mg hydrochlorothiazide + 2.5 mg amiloride)
Study: 6689277
Drug: Hydrochlorothiazide alone
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide alone (25 mg)
Study: 10532693
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose warfarin
Study: 10440141
Drug: Sotalol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (40 patients; mean dose = 190 +/- 43 mg/day)
Study: 10440141
Drug: Placebo (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (45 patients; mean dose = 176 +/- 32 mg/day)
Study: 1599636
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine plus 5 mg enalapril
Study: 23982575
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor physical therapy (PFPT)
Study: 31039482
Drug: Aripiprazole augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole augmentation for 12 weeks
Study: 30378274
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of hyperosmolar rectal lubricant daily for 7 days
Study: 30378274
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral TDF/FTC for 7 days
Study: 30378274
Drug: Both hyperosmolar
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both hyperosmolar lubricant and daily oral TDF/FTC for 7 days
Study: 26300329
Drug: Narrative Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Cognitive Therapy (NCT)
Study: 20301014
Drug: Policosanols (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanols (1 to 20 mg/day)
Study: 16634903
Drug: Methyl aminolaevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT), 2 treatments, 2 weeks apart
Study: 16634903
Drug: Methyl aminolaevulinate-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT)
Study: 11037786
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (co-artemether) - 4 x 4 tablets over 48 hours
Study: 11037786
Drug: Chloroquine -
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine - 4 tablets initially, followed by two tablets each at 6-8, 24, and 48 hours
Study: 7543434
Drug: Screening with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening with alpha‐fetoprotein > or = 20 micrograms/L
Study: 7543434
Drug: Serum alpha‐fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha‐fetoprotein > 20 micrograms/L
Study: 626810
Drug: Ioglycamide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ioglycamide infusion at a rate of 4 mg per kg per min for one hour
Study: 626810
Drug: Ioglycamide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ioglycamide infusion
Study: 31294137
Drug: KBMSI-2 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBMSI-2 (6 g twice per day for 8 weeks)
Study: 26562602
Drug: End-of-treatment outcomes
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment outcomes (abstinence and good clinical outcome during treatment)
Study: 26562602
Drug: Logistic regression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Logistic regression analyses based on good clinical outcome, level of drinking during treatment, age at onset of alcohol dependence, and feeling more energetic
Study: 21469973
Drug: Drospirenone 2
Normalized name: drospirenone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 2 mg / Estradiol 1 mg (DRSP/E2)
Study: 16502051
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel and povidine iodine lavage
Study: 12685672
Drug: Control (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conventional medical treatments)
Study: 10752744
Drug: AT(H) concentrate
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT(H) concentrate infusions every 8 hours to raise plasma level to 175% in the first 72 hours after injury
Study: 10752744
Drug: AT(H) concentrate
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT(H) concentrate infusions
Study: 9373047
Drug: CO2-enriched water
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-enriched water (1000 mg CO2/kg)
Study: 29843811
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (placebo)
Study: 20090776
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (CF) 1052 mg day(‐1) for 6 weeks
Study: 20492527
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream 2%
Study: 16187171
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (3 mg/kg)
Study: 10229004
Drug: rHuEPO (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (both doses)
Study: 1906791
Drug: Temafloxacin 600
Normalized name: temafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 600 mg twice daily for 7 days starting on day 1 of the contraceptive cycle
Study: 6654698
Drug: 18 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g/d of sodium DL‐3‐hydroxybutyrate
Study: 24448036
Drug: Weekly practice
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly practice (once/week for four consecutive weeks)
Study: 22858715
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg OTO-104
Study: 19321493
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg, up to 30 mg)
Study: 15466981
Drug: Combination tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tests of total and percent free PSA
Study: 15466981
Drug: PSA >
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA > 4.0 ng/mL
Study: 11353359
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment groups (EMLA and Music)
Study: 9443116
Drug: High-meat group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-meat group (HMG) - mean meat content of 27 g/day
Study: 9443116
Drug: Low-meat group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-meat group (LMG) - mean meat content of 10 g/day
Study: 29486879
Drug: Propofol TIVA
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TIVA (15.0 ± 4.7 mg/kg/h)
Study: 23652951
Drug: HP802‐247 (5M
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP802‐247 (5M cells/mL) applied weekly
Study: 23652951
Drug: Bacitracin ointment
Normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacitracin ointment applied daily
Study: 20450412
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of oral micronized 17β-estradiol daily for 2 years
Study: 11101175
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide at doses ranging from 200 to 1600 microg administered twice daily for 12 to 20 weeks.
Study: 9299668
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily for 10 days
Study: 8394191
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (0.625 mg/day)
Study: 10368794
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 micrograms/day)
Study: 30397984
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose isotretinoin (20 mg/day)
Study: 30397984
Drug: Conventional high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-dose isotretinoin (0.5 mg/kg/day)
Study: 31080813
Drug: Isotretinoin treatment
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin treatment
Study: 23013946
Drug: Heparin-coated poliacrylonitrile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated poliacrylonitrile AN69ST® membrane without systemic anticoagulation
Study: 23013946
Drug: Heparin-coated poliacrylonitrile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated poliacrylonitrile AN69ST® membrane
Study: 16285357
Drug: Docetaxel chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy every three weeks combined with prednisone
Study: 16285357
Drug: Mitoxantrone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone plus low-dose prednisone
Study: 11977645
Drug: Xeloda (capecitabine)
Normalized name: capecitabine Oral Tablet [Xeloda]
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda (capecitabine) at a dose of 2,510 mg/m2/d, bid, for two weeks followed by one week rest as one cycle.
Study: 11977645
Drug: Xeloda (capecitabine)
Normalized name: capecitabine Oral Tablet [Xeloda]
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Xeloda (capecitabine) in patients who had failed previous chemotherapy with taxanes and/or anthracycline.
Study: 7878283
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 to 10 mg)
Study: 7878283
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate (ATP) (5 to 20 mg)
Study: 2086208
Drug: Fortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified cereal (bovine haemoglobin concentrate, Fe: 14 mg/100 g of powder)
Study: 2086208
Drug: Fortified cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified cereal with additional supplementation of 45 mg Fe for 90 days
Study: 457522
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate (NaNO3) aerosol inhalation
Study: 457522
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (NaCl) aerosol inhalation
Study: 29063244
Drug: Fingolimod (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (0.5 mg daily)
Study: 29063244
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (250 µg every other day)
Study: 23896477
Drug: GSK2336805 (≥10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 (≥10 mg single dose)
Study: 23896477
Drug: GSK2336805 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 (various doses)
Study: 19151049
Drug: Lidocaine/tetracaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine patch (Synera, Rapydan)
Study: 19151049
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (EMLA)
Study: 12211502
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment before 28 weeks of gestation
Study: 19426177
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment after delivery
Study: 8686815
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with low dose fentanyl
Study: 8686815
Drug: Midazolam with
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam with high dose fentanyl
Study: 1753612
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (N=24)
Study: 1753612
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy in combination with hyperbaric oxygenation (N=27)
Study: 1753612
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy in combination with hemosorption (N=26)
Study: 6802557
Drug: Glucose System
Normalized name: Atlast Blood Glucose System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose System (TPN with intravenous glucose)
Study: 6802557
Drug: Lipid System
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid System (TPN with 50% glucose + 50% intravenous fat)
Study: 29141663
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose distribution
Study: 25760874
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min)
Study: 25760874
Drug: Dose-adjusted Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted Vitamin K antagonists (VKAs)
Study: 23432642
Drug: Glycine powder
Normalized name: Nutricia Glycine Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine powder air-polishing (GPAP) for 5 sec in addition to oral hygiene instruction and non-surgical debridement.
Study: 23432642
Drug: Non-surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical debridement and oral hygiene instruction (Control group).
Study: 22989394
Drug: Desmoteplase 90
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 90 μg/kg IV bolus injection
Study: 22989394
Drug: Desmoteplase 70
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase 70 and 90 μg/kg IV bolus injection
Study: 18829988
Drug: Insulin requirements
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin requirements
Study: 15111683
Drug: Ropinirole (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.5 to 6.0 mg/day)
Study: 12196868
Drug: Weekly courses
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly courses of betamethasone until 33 weeks' gestation or delivery
Study: 2692970
Drug: Chewable cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable cimetidine (200 mg)
Study: 2692970
Drug: Chewable antacid
Normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable antacid
Study: 25415290
Drug: Gardasil (HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil (HPV vaccine)
Study: 25415290
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo vaccine
Study: 22815050
Drug: EV-077 0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 0.0125 mg/kg
Study: 22815050
Drug: EV-077 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 0.125 mg/kg
Study: 22815050
Drug: EV-077 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 0.375 mg/kg
Study: 22815050
Drug: EV-077 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 0.75 mg/kg
Study: 22815050
Drug: EV-077 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV-077 1.25 mg/kg